logo
Plus   Neg
Share
Email

Amgen's AMG 145 Lowers Bad Cholesterol Levels

Amgen Inc. (AMGN) Monday said its experimental drug AMG 145 in combination with statin therapy reduced bad cholesterol levels in patients.

AMG 145 is an investigational antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C) or bad cholesterol from the blood.

Amgen in a statement said AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in LDL-C by up to 56 percent in patients with heterozygous familial hypercholesterolemia (HeFH) in the Phase 2 Rutherford study.

HeFH, one of the most common genetic disorder, elevates the cholesterol and LDL-C levels and leads to cardiovascular diseases and death.

The company said treatment with AMG 145 every four weeks resulted in a significant LDL-C decrease versus placebo in HeFH patients on lipid-lowering therapy.

At week 12, LDL-C reduction was 43 percent and 55 percent with AMG 145 350 mg and 420 mg, respectively, compared to a 1 percent increase with placebo arm.

"Despite existing therapies and maintaining a healthy lifestyle, patients with heterozygous familial hypercholesterolemia are prematurely at risk for serious cardiovascular disease due to the difficulty in reducing their LDL-C levels," said Frederick Raal, Carbohydrate & Lipid Metabolism Research Unit, Division of Endocrinology & Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Deutsche Bank were losing around 2 percent in German trading after the banking giant reported lower profit and revenues in its first quarter with weakness in all segments, mainly Corporate & Investment Bank. Separately, the bank announced actions to reshape its Corporate & Investment Bank and additional cost-cutting measures, including job cuts. Hershey Co. (HSY) on Thursday reaffirmed its adjusted earnings guidance for the full-year 2018 in the range of $5.33 to $5.43 range, an increase of 14 to 16 percent from 2017. However, reported earnings are now expected to be in the range of $4.73 to $4.98 per share, an increase of $0.02 per share... Automaker General Motors Co. on Thursday reported a 60 percent fall in profit for the first quarter from last year, reflecting lower revenues and a charge related to the company's Korean operations restructuring. However, adjusted earnings per share for the quarter beat analysts' estimates and the company affirmed its financial outlook for fiscal 2018.
Follow RTT